{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:15:44Z","timestamp":1793232944423,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T00:00:00Z","timestamp":1669507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T00:00:00Z","timestamp":1669507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP16K10596"],"award-info":[{"award-number":["JP16K10596"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP16H05416"],"award-info":[{"award-number":["JP16H05416"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["17ck0106285h0001"],"award-info":[{"award-number":["17ck0106285h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s00262-022-03334-x","type":"journal-article","created":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T20:59:20Z","timestamp":1669582760000},"page":"1285-1300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer"],"prefix":"10.1007","volume":"72","author":[{"given":"Yoshinori","family":"Kajiwara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiko","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Kanaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Fushimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Noma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzo","family":"Umeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Urata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Kagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyoshi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,27]]},"reference":[{"key":"3334_CR1","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74:2913\u20132921. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-0155","journal-title":"Cancer Res"},{"key":"3334_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer Statistics, 2021. CA Cancer J Clin 71:7\u201333. https:\/\/doi.org\/10.3322\/caac.21654","journal-title":"CA Cancer J Clin"},{"key":"3334_CR3","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris 3rd","year":"1997","unstructured":"Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403\u20132413. https:\/\/doi.org\/10.1200\/JCO.1997.15.6.2403","journal-title":"J Clin Oncol"},{"key":"3334_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.canlet.2021.08.029","volume":"521","author":"Z Gu","year":"2021","unstructured":"Gu Z, Du Y, Zhao X, Wang C (2021) Tumor microenvironment and metabolic remodeling in gemcitabine-based chemoresistance of pancreatic cancer. Cancer Lett 521:98\u2013108. https:\/\/doi.org\/10.1016\/j.canlet.2021.08.029","journal-title":"Cancer Lett"},{"key":"3334_CR5","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","volume":"48","author":"C Sun","year":"2018","unstructured":"Sun C, Mezzadra R, Schumacher TN (2018) Regulation and function of the PD-L1 checkpoint. Immunity 48:434\u2013452. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.014","journal-title":"Immunity"},{"key":"3334_CR6","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/s41590-020-0761-y","volume":"21","author":"J Leinwand","year":"2020","unstructured":"Leinwand J, Miller G (2020) Regulation and modulation of antitumor immunity in pancreatic cancer. Nat Immunol 21:1152\u20131159. https:\/\/doi.org\/10.1038\/s41590-020-0761-y","journal-title":"Nat Immunol"},{"key":"3334_CR7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst RS, Soria JC, Kowanetz M et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563\u2013567. https:\/\/doi.org\/10.1038\/nature14011","journal-title":"Nature"},{"key":"3334_CR8","doi-asserted-by":"publisher","first-page":"e126908","DOI":"10.1172\/jci.insight.126908","volume":"4","author":"M Yarchoan","year":"2019","unstructured":"Yarchoan M, Albacker LA, Hopkins AC et al (2019) PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight 4:e126908. https:\/\/doi.org\/10.1172\/jci.insight.126908","journal-title":"JCI Insight"},{"key":"3334_CR9","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.3390\/cancers13122995","volume":"13","author":"L Gorchs","year":"2021","unstructured":"Gorchs L, Kaipe H (2021) Interactions between cancer-associated fibroblasts and T cells in the pancreatic tumor microenvironment and the role of chemokines. Cancers (Basel) 13:2995. https:\/\/doi.org\/10.3390\/cancers13122995","journal-title":"Cancers (Basel)"},{"key":"3334_CR10","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1073\/pnas.1811067116","volume":"116","author":"J Blando","year":"2019","unstructured":"Blando J, Sharma A, Higa MG et al (2019) Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci USA 116:1692\u20131697. https:\/\/doi.org\/10.1073\/pnas.1811067116","journal-title":"Proc Natl Acad Sci USA"},{"key":"3334_CR11","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1136\/gutjnl-2013-306271","volume":"63","author":"IM Stromnes","year":"2014","unstructured":"Stromnes IM, Brockenbrough JS, Izeradjene K, Carlson MA, Cuevas C, Simmons RM, Greenberg PD, Hingorani SR (2014) Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut 63:1769\u20131781. https:\/\/doi.org\/10.1136\/gutjnl-2013-306271","journal-title":"Gut"},{"key":"3334_CR12","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.celrep.2018.03.131","volume":"23","author":"JB Candido","year":"2018","unstructured":"Candido JB, Morton JP, Bailey P et al (2018) CSF1R(+) macrophages sustain pancreatic tumor growth through T cell suppression and maintenance of key gene programs that define the squamous subtype. Cell Rep 23:1448\u20131460. https:\/\/doi.org\/10.1016\/j.celrep.2018.03.131","journal-title":"Cell Rep"},{"key":"3334_CR13","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1245\/s10434-006-9015-y","volume":"13","author":"CT Viehl","year":"2006","unstructured":"Viehl CT, Moore TT, Liyanage UK, Frey DM, Ehlers JP, Eberlein TJ, Goedegebuure PS, Linehan DC (2006) Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. Ann Surg Oncol 13:1252\u20131258. https:\/\/doi.org\/10.1245\/s10434-006-9015-y","journal-title":"Ann Surg Oncol"},{"key":"3334_CR14","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3892\/or.2017.5399","volume":"37","author":"T Doi","year":"2017","unstructured":"Doi T, Ishikawa T, Okayama T et al (2017) The JAK\/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines. Oncol Rep 37:545\u2013554. https:\/\/doi.org\/10.3892\/or.2017.5399","journal-title":"Oncol Rep"},{"key":"3334_CR15","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1158\/0008-5472.CAN-14-2921","volume":"75","author":"S Takeuchi","year":"2015","unstructured":"Takeuchi S, Baghdadi M, Tsuchikawa T et al (2015) Chemotherapy-derived inflammatory responses accelerate the formation of immunosuppressive myeloid cells in the tissue microenvironment of human pancreatic cancer. Cancer Res 75:2629\u20132640. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-2921","journal-title":"Cancer Res"},{"key":"3334_CR16","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR et al (2002) Tumor-associated B7\u2013H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793\u2013800. https:\/\/doi.org\/10.1038\/nm730","journal-title":"Nat Med"},{"key":"3334_CR17","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162\u2013174. https:\/\/doi.org\/10.1038\/nri2506","journal-title":"Nat Rev Immunol"},{"key":"3334_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/OV.S53858","volume":"3","author":"JW Ady","year":"2014","unstructured":"Ady JW, Heffner J, Klein E, Fong Y (2014) Oncolytic viral therapy for pancreatic cancer: current research and future directions. Oncolytic Virother 3:35\u201346. https:\/\/doi.org\/10.2147\/OV.S53858","journal-title":"Oncolytic Virother"},{"key":"3334_CR19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.canlet.2018.07.006","volume":"434","author":"CB Nattress","year":"2018","unstructured":"Nattress CB, Hallden G (2018) Advances in oncolytic adenovirus therapy for pancreatic cancer. Cancer Lett 434:56\u201369. https:\/\/doi.org\/10.1016\/j.canlet.2018.07.006","journal-title":"Cancer Lett"},{"key":"3334_CR20","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.3390\/v12111318","volume":"12","author":"SD Haller","year":"2020","unstructured":"Haller SD, Monaco ML, Essani K (2020) The present status of immuno-oncolytic viruses in the treatment of pancreatic cancer. Viruses 12:1318. https:\/\/doi.org\/10.3390\/v12111318","journal-title":"Viruses"},{"key":"3334_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1158\/1078-0432.ccr-1075-3","volume":"10","author":"T Kawashima","year":"2004","unstructured":"Kawashima T, Kagawa S, Kobayashi N et al (2004) Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 10:285\u2013292. https:\/\/doi.org\/10.1158\/1078-0432.ccr-1075-3","journal-title":"Clin Cancer Res"},{"key":"3334_CR22","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1349-7006.2007.00665.x","volume":"99","author":"Y Hashimoto","year":"2008","unstructured":"Hashimoto Y, Watanabe Y, Shirakiya Y et al (2008) Establishment of biological and pharmacokinetic assays of telomerase-specific replication-selective adenovirus. Cancer Sci 99:385\u2013390. https:\/\/doi.org\/10.1111\/j.1349-7006.2007.00665.x","journal-title":"Cancer Sci"},{"key":"3334_CR23","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1016\/j.ejca.2011.12.020","volume":"48","author":"Y Yamasaki","year":"2012","unstructured":"Yamasaki Y, Tazawa H, Hashimoto Y et al (2012) A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression. Eur J Cancer 48:2282\u20132291. https:\/\/doi.org\/10.1016\/j.ejca.2011.12.020","journal-title":"Eur J Cancer"},{"key":"3334_CR24","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1158\/1535-7163.MCT-12-0869","volume":"12","author":"J Hasei","year":"2013","unstructured":"Hasei J, Sasaki T, Tazawa H et al (2013) Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells. Mol Cancer Ther 12:314\u2013325. https:\/\/doi.org\/10.1158\/1535-7163.MCT-12-0869","journal-title":"Mol Cancer Ther"},{"key":"3334_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.omto.2020.03.016","volume":"17","author":"T Koujima","year":"2020","unstructured":"Koujima T, Tazawa H, Ieda T et al (2020) Oncolytic virus-mediated targeting of the ERK signaling pathway inhibits invasive propensity in human pancreatic cancer. Mol Ther Oncolytics 17:107\u2013117. https:\/\/doi.org\/10.1016\/j.omto.2020.03.016","journal-title":"Mol Ther Oncolytics"},{"key":"3334_CR26","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.ymthe.2020.01.003","volume":"28","author":"N Kanaya","year":"2020","unstructured":"Kanaya N, Kuroda S, Kakiuchi Y et al (2020) Immune modulation by telomerase-specific oncolytic adenovirus synergistically enhances antitumor efficacy with Anti-PD1 antibody. Mol Ther 28:794\u2013804. https:\/\/doi.org\/10.1016\/j.ymthe.2020.01.003","journal-title":"Mol Ther"},{"key":"3334_CR27","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.ccr.2012.04.025","volume":"21","author":"LJ Bayne","year":"2012","unstructured":"Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, Vonderheide RH (2012) Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21:822\u2013835. https:\/\/doi.org\/10.1016\/j.ccr.2012.04.025","journal-title":"Cancer Cell"},{"key":"3334_CR28","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.ccr.2012.04.024","volume":"21","author":"Y Pylayeva-Gupta","year":"2012","unstructured":"Pylayeva-Gupta Y, Lee KE, Hajdu CH, Miller G, Bar-Sagi D (2012) Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21:836\u2013847. https:\/\/doi.org\/10.1016\/j.ccr.2012.04.024","journal-title":"Cancer Cell"},{"key":"3334_CR29","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1128\/mcb.10.3.1281-1286.1990","volume":"10","author":"R Schreck","year":"1990","unstructured":"Schreck R, Baeuerle PA (1990) NF-kappa B as inducible transcriptional activator of the granulocyte-macrophage colony-stimulating factor gene. Mol Cell Biol 10:1281\u20131286. https:\/\/doi.org\/10.1128\/mcb.10.3.1281-1286.1990","journal-title":"Mol Cell Biol"},{"key":"3334_CR30","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1158\/1078-0432.CCR-06-2746","volume":"13","author":"T Nomi","year":"2007","unstructured":"Nomi T, Sho M, Akahori T et al (2007) Clinical significance and therapeutic potential of the programmed death-1 ligand\/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 13:2151\u20132157. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2746","journal-title":"Clin Cancer Res"},{"key":"3334_CR31","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/2326-6066.CIR-18-0822","volume":"7","author":"L Danilova","year":"2019","unstructured":"Danilova L, Ho WJ, Zhu Q et al (2019) Programmed cell death ligand-1 (PD-L1) and CD8 expression profiling identify an immunologic subtype of pancreatic ductal adenocarcinomas with favorable survival. Cancer Immunol Res 7:886\u2013895. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0822","journal-title":"Cancer Immunol Res"},{"key":"3334_CR32","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1111\/cas.14197","volume":"110","author":"H Sato","year":"2019","unstructured":"Sato H, Jeggo PA, Shibata A (2019) Regulation of programmed death-ligand 1 expression in response to DNA damage in cancer cells: Implications for precision medicine. Cancer Sci 110:3415\u20133423. https:\/\/doi.org\/10.1111\/cas.14197","journal-title":"Cancer Sci"},{"key":"3334_CR33","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3892\/mmr.2012.970","volume":"6","author":"F Wang","year":"2012","unstructured":"Wang F, Ma J, Liu J, Jin H, Huang D (2012) Synthetic small peptides acting on B7H1 enhance apoptosis in pancreatic cancer cells. Mol Med Rep 6:553\u2013557. https:\/\/doi.org\/10.3892\/mmr.2012.970","journal-title":"Mol Med Rep"},{"key":"3334_CR34","doi-asserted-by":"publisher","first-page":"605619","DOI":"10.3389\/fimmu.2020.605619","volume":"11","author":"RH Vonderheide","year":"2020","unstructured":"Vonderheide RH, Bear AS (2020) Tumor-derived myeloid cell chemoattractants and T cell exclusion in pancreatic cancer. Front Immunol 11:605619. https:\/\/doi.org\/10.3389\/fimmu.2020.605619","journal-title":"Front Immunol"},{"key":"3334_CR35","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00262-013-1407-9","volume":"62","author":"T Ghansah","year":"2013","unstructured":"Ghansah T, Vohra N, Kinney K, Weber A, Kodumudi K, Springett G, Sarnaik AA, Pilon-Thomas S (2013) Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma. Cancer Immunol Immunother 62:1083\u20131091. https:\/\/doi.org\/10.1007\/s00262-013-1407-9","journal-title":"Cancer Immunol Immunother"},{"key":"3334_CR36","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12967-016-1037-z","volume":"14","author":"E Eriksson","year":"2016","unstructured":"Eriksson E, Wenthe J, Irenaeus S, Loskog A, Ullenhag G (2016) Gemcitabine reduces MDSCs, tregs and TGFbeta-1 while restoring the teff\/treg ratio in patients with pancreatic cancer. J Transl Med 14:282. https:\/\/doi.org\/10.1186\/s12967-016-1037-z","journal-title":"J Transl Med"},{"key":"3334_CR37","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s00262-011-1178-0","volume":"61","author":"MR Porembka","year":"2012","unstructured":"Porembka MR, Mitchem JB, Belt BA, Hsieh CS, Lee HM, Herndon J, Gillanders WE, Linehan DC, Goedegebuure P (2012) Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother 61:1373\u20131385. https:\/\/doi.org\/10.1007\/s00262-011-1178-0","journal-title":"Cancer Immunol Immunother"},{"key":"3334_CR38","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1158\/2326-6066.CIR-18-0070","volume":"6","author":"BJ Christmas","year":"2018","unstructured":"Christmas BJ, Rafie CI, Hopkins AC et al (2018) Entinostat converts immune-resistant breast and pancreatic cancers into checkpoint-responsive tumors by reprogramming tumor-infiltrating MDSCs. Cancer Immunol Res 6:1561\u20131577. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0070","journal-title":"Cancer Immunol Res"},{"key":"3334_CR39","doi-asserted-by":"publisher","first-page":"212","DOI":"10.4049\/jimmunol.1900930","volume":"204","author":"C Wu","year":"2020","unstructured":"Wu C, Tan X, Hu X, Zhou M, Yan J, Ding C (2020) Tumor microenvironment following gemcitabine treatment favors differentiation of immunosuppressive Ly6C(high) myeloid cells. J Immunol 204:212\u2013223. https:\/\/doi.org\/10.4049\/jimmunol.1900930","journal-title":"J Immunol"},{"key":"3334_CR40","doi-asserted-by":"publisher","first-page":"619253","DOI":"10.3389\/fimmu.2020.619253","volume":"11","author":"N Fultang","year":"2020","unstructured":"Fultang N, Li X, Li T, Chen YH (2020) Myeloid-derived suppressor cell differentiation in cancer: transcriptional regulators and enhanceosome-mediated mechanisms. Front Immunol 11:619253. https:\/\/doi.org\/10.3389\/fimmu.2020.619253","journal-title":"Front Immunol"},{"key":"3334_CR41","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1158\/0008-5472.CAN-12-4601","volume":"73","author":"TA Mace","year":"2013","unstructured":"Mace TA, Ameen Z, Collins A et al (2013) Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res 73:3007\u20133018. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-4601","journal-title":"Cancer Res"},{"key":"3334_CR42","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.omto.2022.04.009","volume":"25","author":"T Ogawa","year":"2022","unstructured":"Ogawa T, Kikuchi S, Tabuchi M et al (2022) Modulation of p53 expression in cancer-associated fibroblasts prevents peritoneal metastasis of gastric cancer. Mol Ther Oncolytics 25:249\u2013261. https:\/\/doi.org\/10.1016\/j.omto.2022.04.009","journal-title":"Mol Ther Oncolytics"},{"key":"3334_CR43","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.4049\/jimmunol.182.3.1746","volume":"182","author":"MC Tan","year":"2009","unstructured":"Tan MC, Goedegebuure PS, Belt BA, Flaherty B, Sankpal N, Gillanders WE, Eberlein TJ, Hsieh CS, Linehan DC (2009) Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol 182:1746\u20131755. https:\/\/doi.org\/10.4049\/jimmunol.182.3.1746","journal-title":"J Immunol"},{"key":"3334_CR44","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1038\/onc.2016.458","volume":"36","author":"X Wang","year":"2017","unstructured":"Wang X, Lang M, Zhao T et al (2017) Cancer-FOXP3 directly activated CCL5 to recruit FOXP3(+)Treg cells in pancreatic ductal adenocarcinoma. Oncogene 36:3048\u20133058. https:\/\/doi.org\/10.1038\/onc.2016.458","journal-title":"Oncogene"},{"key":"3334_CR45","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41392-020-0144-8","volume":"5","author":"X Wang","year":"2020","unstructured":"Wang X, Li X, Wei X et al (2020) PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC. Signal Transduct Target Ther 5:38. https:\/\/doi.org\/10.1038\/s41392-020-0144-8","journal-title":"Signal Transduct Target Ther"},{"key":"3334_CR46","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1089\/jir.2014.0149","volume":"35","author":"P Bhattacharya","year":"2015","unstructured":"Bhattacharya P, Budnick I, Singh M, Thiruppathi M, Alharshawi K, Elshabrawy H, Holterman MJ, Prabhakar BS (2015) Dual role of GM-CSF as a pro-inflammatory and a regulatory cytokine: implications for immune therapy. J Interferon Cytokine Res 35:585\u2013599. https:\/\/doi.org\/10.1089\/jir.2014.0149","journal-title":"J Interferon Cytokine Res"},{"key":"3334_CR47","doi-asserted-by":"publisher","first-page":"6337","DOI":"10.1158\/0008-5472.CAN-04-0757","volume":"64","author":"P Serafini","year":"2004","unstructured":"Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I (2004) High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 64:6337\u20136343. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-0757","journal-title":"Cancer Res"},{"key":"3334_CR48","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1158\/1078-0432.CCR-19-3978","volume":"26","author":"T Tsujikawa","year":"2020","unstructured":"Tsujikawa T, Crocenzi T, Durham JN et al (2020) Evaluation of cyclophosphamide\/gvax pancreas followed by Listeria\u2013Mesothelin (CRS-207) with or without Nivolumab in patients with pancreatic cancer. Clin Cancer Res 26:3578\u20133588. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3978","journal-title":"Clin Cancer Res"},{"key":"3334_CR49","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.canlet.2018.10.045","volume":"445","author":"J Jiang","year":"2019","unstructured":"Jiang J, Zhou H, Ni C, Hu X, Mou Y, Huang D, Yang L (2019) Immunotherapy in pancreatic cancer: new hope or mission impossible? Cancer Lett 445:57\u201364. https:\/\/doi.org\/10.1016\/j.canlet.2018.10.045","journal-title":"Cancer Lett"},{"key":"3334_CR50","doi-asserted-by":"publisher","first-page":"167","DOI":"10.15252\/emmm.201606674","volume":"9","author":"A Azad","year":"2017","unstructured":"Azad A, Yin Lim S, D\u2019Costa Z, et al (2017) PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. EMBO Mol Med 9:167\u2013180. https:\/\/doi.org\/10.15252\/emmm.201606674","journal-title":"EMBO Mol Med"},{"key":"3334_CR51","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00280-021-04310-5","volume":"88","author":"K Sugiu","year":"2021","unstructured":"Sugiu K, Tazawa H, Hasei J et al (2021) Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression. Cancer Chemother Pharmacol 88:513\u2013524. https:\/\/doi.org\/10.1007\/s00280-021-04310-5","journal-title":"Cancer Chemother Pharmacol"},{"key":"3334_CR52","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1158\/1535-7163.MCT-08-0901","volume":"8","author":"D Liu","year":"2009","unstructured":"Liu D, Kojima T, Ouchi M, Kuroda S, Watanabe Y, Hashimoto Y, Onimatsu H, Urata Y, Fujiwara T (2009) Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer. Mol Cancer Ther 8:980\u2013987. https:\/\/doi.org\/10.1158\/1535-7163.MCT-08-0901","journal-title":"Mol Cancer Ther"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03334-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-022-03334-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03334-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T15:12:45Z","timestamp":1681744365000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-022-03334-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,27]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["3334"],"URL":"https:\/\/doi.org\/10.1007\/s00262-022-03334-x","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,27]]},"assertion":[{"value":"12 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y. Urata is President & CEO of Oncolys BioPharma Inc. H. Tazawa and T. Fujiwara are consultants of Oncolys BioPharma Inc. The other authors have no potential conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Y. Urata is President & CEO of Oncolys BioPharma Inc. H. Tazawa and T. Fujiwara are consultants of Oncolys BioPharma Inc. The other authors have no potential conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}